The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study
Tetracyclines and clindamycin plus rifampicin combination therapy are both considered first-line therapy in current hidradenitis suppurativa guidelines. However, evidence for their efficacy is drawn from small studies, often without validated outcomes. To assess the 12-week efficacy of oral tetracyc...
Gespeichert in:
| Veröffentlicht in: | Journal of the American Academy of Dermatology 2021-08, Vol.85 (2), p.369-378 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 378 |
|---|---|
| container_issue | 2 |
| container_start_page | 369 |
| container_title | Journal of the American Academy of Dermatology |
| container_volume | 85 |
| creator | van Straalen, Kelsey R. Tzellos, Thrasyvoulos Guillem, Phillipe Benhadou, Farida Cuenca-Barrales, Carlos Daxhelet, Mathilde Daoud, Mathieu Efthymiou, Ourania Giamarellos-Bourboulis, Evangelos J. Jemec, Gregor B.E. Katoulis, Alexandros C. Koenig, Anke Lazaridou, Elizabeth Marzano, Angelo V. Matusiak, Łucas Molina-Leyva, Alejandro Moltrasio, Chiara Pinter, Andreas Potenza, Concetta Romaní, Jorge Saunte, Ditte M. Skroza, Nevena Stergianou, Dimitra Szepietowski, Jacek Trigoni, Anastasia Vilarrasa, Eva van der Zee, Hessel H. |
| description | Tetracyclines and clindamycin plus rifampicin combination therapy are both considered first-line therapy in current hidradenitis suppurativa guidelines. However, evidence for their efficacy is drawn from small studies, often without validated outcomes.
To assess the 12-week efficacy of oral tetracyclines and a combination of clindamycin and rifampicin.
A prospective, international cohort study performed between October 2018 and August 2019.
In total, 63.6% of the included 283 patients received oral tetracyclines, and 36.4% were treated with clindamycin and rifampicin. Both groups showed a significant decrease in International Hidradenitis Suppurativa Severity Score System from baseline (both P |
| doi_str_mv | 10.1016/j.jaad.2020.12.089 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2480265125</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0190962221001766</els_id><sourcerecordid>2480265125</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-3204f2c008df28fecb50c78dca008b4e817ade4aceb836e79024d0613bdc5ce83</originalsourceid><addsrcrecordid>eNp9kctuFDEQRa0IlAyBH2CBvGTTQ9nt6XYjNihKAlIkJBTWltsuazzqF35E6n_iI3EzgSUr21Wnrm75EvKWwZ4Baz6c9iet7Z4DLwW-B9ldkB2Drq2aVrYvyA5YB1XXcH5FXsV4AoBO1O0luaprIUXbNDvy6_GIFJ3zRpuV6snSNA8YdO8Hn1Y6O5owhdIzg58w_iG2q9XjavxElyFHGrzT4-K3t5sDTUUyBdRpxCltEkdvg7Y4-eQjjXlZctDJP-mP9DvGPKS4QZouYY4LmtJBepvDvKCeqJmPc0g0pmzX1-Sl00PEN8_nNflxd_t486V6-Hb_9ebzQ2UEQKpqDsJxAyCt49Kh6Q9gWmmNLqVeoGRtcSO0wV7WDbYdcGGhYXVvzcGgrK_J-7NucfQzY0xq9NHgMOgJ5xwVFxJ4c2D8UFB-Rk0xHwM6tQQ_6rAqBmpLSZ3UlpLaUlKMq5JSGXr3rJ_7Ee2_kb-xFODTGcCy5ZPHoKLxOBm0PpQPUnb2_9P_DRr4qOo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2480265125</pqid></control><display><type>article</type><title>The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study</title><source>Elsevier ScienceDirect Journals</source><creator>van Straalen, Kelsey R. ; Tzellos, Thrasyvoulos ; Guillem, Phillipe ; Benhadou, Farida ; Cuenca-Barrales, Carlos ; Daxhelet, Mathilde ; Daoud, Mathieu ; Efthymiou, Ourania ; Giamarellos-Bourboulis, Evangelos J. ; Jemec, Gregor B.E. ; Katoulis, Alexandros C. ; Koenig, Anke ; Lazaridou, Elizabeth ; Marzano, Angelo V. ; Matusiak, Łucas ; Molina-Leyva, Alejandro ; Moltrasio, Chiara ; Pinter, Andreas ; Potenza, Concetta ; Romaní, Jorge ; Saunte, Ditte M. ; Skroza, Nevena ; Stergianou, Dimitra ; Szepietowski, Jacek ; Trigoni, Anastasia ; Vilarrasa, Eva ; van der Zee, Hessel H.</creator><creatorcontrib>van Straalen, Kelsey R. ; Tzellos, Thrasyvoulos ; Guillem, Phillipe ; Benhadou, Farida ; Cuenca-Barrales, Carlos ; Daxhelet, Mathilde ; Daoud, Mathieu ; Efthymiou, Ourania ; Giamarellos-Bourboulis, Evangelos J. ; Jemec, Gregor B.E. ; Katoulis, Alexandros C. ; Koenig, Anke ; Lazaridou, Elizabeth ; Marzano, Angelo V. ; Matusiak, Łucas ; Molina-Leyva, Alejandro ; Moltrasio, Chiara ; Pinter, Andreas ; Potenza, Concetta ; Romaní, Jorge ; Saunte, Ditte M. ; Skroza, Nevena ; Stergianou, Dimitra ; Szepietowski, Jacek ; Trigoni, Anastasia ; Vilarrasa, Eva ; van der Zee, Hessel H.</creatorcontrib><description>Tetracyclines and clindamycin plus rifampicin combination therapy are both considered first-line therapy in current hidradenitis suppurativa guidelines. However, evidence for their efficacy is drawn from small studies, often without validated outcomes.
To assess the 12-week efficacy of oral tetracyclines and a combination of clindamycin and rifampicin.
A prospective, international cohort study performed between October 2018 and August 2019.
In total, 63.6% of the included 283 patients received oral tetracyclines, and 36.4% were treated with clindamycin and rifampicin. Both groups showed a significant decrease in International Hidradenitis Suppurativa Severity Score System from baseline (both P < .001). The Hidradenitis Suppurativa Clinical Response (HiSCR) was achieved in 40.1% and 48.2% of patients, respectively (P = .26). Patient characteristics or disease severity were not associated with the attainment of HiSCR or the minimal clinically important differences for the Dermatology Life Quality Index and pain.
Cohort study. Respectively, 23.9% and 19.4% of patients had to be excluded from the HiSCR analysis for the tetracycline and combination therapy group because of a low abscess and nodule count at baseline.
This study shows significant efficacy of both tetracycline treatment and clindamycin and rifampicin combination therapy after 12 weeks in patients with hidradenitis suppurativa. No significant differences in efficacy were observed between the 2 treatments, regardless of disease severity.</description><identifier>ISSN: 0190-9622</identifier><identifier>EISSN: 1097-6787</identifier><identifier>DOI: 10.1016/j.jaad.2020.12.089</identifier><identifier>PMID: 33484766</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>acne inversa ; antibiotics ; clindamycin ; doxycycline ; efficacy ; guideline ; minocycline ; outcome ; rifampicin ; tetracycline ; therapy ; treatment</subject><ispartof>Journal of the American Academy of Dermatology, 2021-08, Vol.85 (2), p.369-378</ispartof><rights>2021 American Academy of Dermatology, Inc.</rights><rights>Copyright © 2021. Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-3204f2c008df28fecb50c78dca008b4e817ade4aceb836e79024d0613bdc5ce83</citedby><cites>FETCH-LOGICAL-c400t-3204f2c008df28fecb50c78dca008b4e817ade4aceb836e79024d0613bdc5ce83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0190962221001766$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33484766$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Straalen, Kelsey R.</creatorcontrib><creatorcontrib>Tzellos, Thrasyvoulos</creatorcontrib><creatorcontrib>Guillem, Phillipe</creatorcontrib><creatorcontrib>Benhadou, Farida</creatorcontrib><creatorcontrib>Cuenca-Barrales, Carlos</creatorcontrib><creatorcontrib>Daxhelet, Mathilde</creatorcontrib><creatorcontrib>Daoud, Mathieu</creatorcontrib><creatorcontrib>Efthymiou, Ourania</creatorcontrib><creatorcontrib>Giamarellos-Bourboulis, Evangelos J.</creatorcontrib><creatorcontrib>Jemec, Gregor B.E.</creatorcontrib><creatorcontrib>Katoulis, Alexandros C.</creatorcontrib><creatorcontrib>Koenig, Anke</creatorcontrib><creatorcontrib>Lazaridou, Elizabeth</creatorcontrib><creatorcontrib>Marzano, Angelo V.</creatorcontrib><creatorcontrib>Matusiak, Łucas</creatorcontrib><creatorcontrib>Molina-Leyva, Alejandro</creatorcontrib><creatorcontrib>Moltrasio, Chiara</creatorcontrib><creatorcontrib>Pinter, Andreas</creatorcontrib><creatorcontrib>Potenza, Concetta</creatorcontrib><creatorcontrib>Romaní, Jorge</creatorcontrib><creatorcontrib>Saunte, Ditte M.</creatorcontrib><creatorcontrib>Skroza, Nevena</creatorcontrib><creatorcontrib>Stergianou, Dimitra</creatorcontrib><creatorcontrib>Szepietowski, Jacek</creatorcontrib><creatorcontrib>Trigoni, Anastasia</creatorcontrib><creatorcontrib>Vilarrasa, Eva</creatorcontrib><creatorcontrib>van der Zee, Hessel H.</creatorcontrib><title>The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study</title><title>Journal of the American Academy of Dermatology</title><addtitle>J Am Acad Dermatol</addtitle><description>Tetracyclines and clindamycin plus rifampicin combination therapy are both considered first-line therapy in current hidradenitis suppurativa guidelines. However, evidence for their efficacy is drawn from small studies, often without validated outcomes.
To assess the 12-week efficacy of oral tetracyclines and a combination of clindamycin and rifampicin.
A prospective, international cohort study performed between October 2018 and August 2019.
In total, 63.6% of the included 283 patients received oral tetracyclines, and 36.4% were treated with clindamycin and rifampicin. Both groups showed a significant decrease in International Hidradenitis Suppurativa Severity Score System from baseline (both P < .001). The Hidradenitis Suppurativa Clinical Response (HiSCR) was achieved in 40.1% and 48.2% of patients, respectively (P = .26). Patient characteristics or disease severity were not associated with the attainment of HiSCR or the minimal clinically important differences for the Dermatology Life Quality Index and pain.
Cohort study. Respectively, 23.9% and 19.4% of patients had to be excluded from the HiSCR analysis for the tetracycline and combination therapy group because of a low abscess and nodule count at baseline.
This study shows significant efficacy of both tetracycline treatment and clindamycin and rifampicin combination therapy after 12 weeks in patients with hidradenitis suppurativa. No significant differences in efficacy were observed between the 2 treatments, regardless of disease severity.</description><subject>acne inversa</subject><subject>antibiotics</subject><subject>clindamycin</subject><subject>doxycycline</subject><subject>efficacy</subject><subject>guideline</subject><subject>minocycline</subject><subject>outcome</subject><subject>rifampicin</subject><subject>tetracycline</subject><subject>therapy</subject><subject>treatment</subject><issn>0190-9622</issn><issn>1097-6787</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kctuFDEQRa0IlAyBH2CBvGTTQ9nt6XYjNihKAlIkJBTWltsuazzqF35E6n_iI3EzgSUr21Wnrm75EvKWwZ4Baz6c9iet7Z4DLwW-B9ldkB2Drq2aVrYvyA5YB1XXcH5FXsV4AoBO1O0luaprIUXbNDvy6_GIFJ3zRpuV6snSNA8YdO8Hn1Y6O5owhdIzg58w_iG2q9XjavxElyFHGrzT4-K3t5sDTUUyBdRpxCltEkdvg7Y4-eQjjXlZctDJP-mP9DvGPKS4QZouYY4LmtJBepvDvKCeqJmPc0g0pmzX1-Sl00PEN8_nNflxd_t486V6-Hb_9ebzQ2UEQKpqDsJxAyCt49Kh6Q9gWmmNLqVeoGRtcSO0wV7WDbYdcGGhYXVvzcGgrK_J-7NucfQzY0xq9NHgMOgJ5xwVFxJ4c2D8UFB-Rk0xHwM6tQQ_6rAqBmpLSZ3UlpLaUlKMq5JSGXr3rJ_7Ee2_kb-xFODTGcCy5ZPHoKLxOBm0PpQPUnb2_9P_DRr4qOo</recordid><startdate>20210801</startdate><enddate>20210801</enddate><creator>van Straalen, Kelsey R.</creator><creator>Tzellos, Thrasyvoulos</creator><creator>Guillem, Phillipe</creator><creator>Benhadou, Farida</creator><creator>Cuenca-Barrales, Carlos</creator><creator>Daxhelet, Mathilde</creator><creator>Daoud, Mathieu</creator><creator>Efthymiou, Ourania</creator><creator>Giamarellos-Bourboulis, Evangelos J.</creator><creator>Jemec, Gregor B.E.</creator><creator>Katoulis, Alexandros C.</creator><creator>Koenig, Anke</creator><creator>Lazaridou, Elizabeth</creator><creator>Marzano, Angelo V.</creator><creator>Matusiak, Łucas</creator><creator>Molina-Leyva, Alejandro</creator><creator>Moltrasio, Chiara</creator><creator>Pinter, Andreas</creator><creator>Potenza, Concetta</creator><creator>Romaní, Jorge</creator><creator>Saunte, Ditte M.</creator><creator>Skroza, Nevena</creator><creator>Stergianou, Dimitra</creator><creator>Szepietowski, Jacek</creator><creator>Trigoni, Anastasia</creator><creator>Vilarrasa, Eva</creator><creator>van der Zee, Hessel H.</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20210801</creationdate><title>The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study</title><author>van Straalen, Kelsey R. ; Tzellos, Thrasyvoulos ; Guillem, Phillipe ; Benhadou, Farida ; Cuenca-Barrales, Carlos ; Daxhelet, Mathilde ; Daoud, Mathieu ; Efthymiou, Ourania ; Giamarellos-Bourboulis, Evangelos J. ; Jemec, Gregor B.E. ; Katoulis, Alexandros C. ; Koenig, Anke ; Lazaridou, Elizabeth ; Marzano, Angelo V. ; Matusiak, Łucas ; Molina-Leyva, Alejandro ; Moltrasio, Chiara ; Pinter, Andreas ; Potenza, Concetta ; Romaní, Jorge ; Saunte, Ditte M. ; Skroza, Nevena ; Stergianou, Dimitra ; Szepietowski, Jacek ; Trigoni, Anastasia ; Vilarrasa, Eva ; van der Zee, Hessel H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-3204f2c008df28fecb50c78dca008b4e817ade4aceb836e79024d0613bdc5ce83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>acne inversa</topic><topic>antibiotics</topic><topic>clindamycin</topic><topic>doxycycline</topic><topic>efficacy</topic><topic>guideline</topic><topic>minocycline</topic><topic>outcome</topic><topic>rifampicin</topic><topic>tetracycline</topic><topic>therapy</topic><topic>treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van Straalen, Kelsey R.</creatorcontrib><creatorcontrib>Tzellos, Thrasyvoulos</creatorcontrib><creatorcontrib>Guillem, Phillipe</creatorcontrib><creatorcontrib>Benhadou, Farida</creatorcontrib><creatorcontrib>Cuenca-Barrales, Carlos</creatorcontrib><creatorcontrib>Daxhelet, Mathilde</creatorcontrib><creatorcontrib>Daoud, Mathieu</creatorcontrib><creatorcontrib>Efthymiou, Ourania</creatorcontrib><creatorcontrib>Giamarellos-Bourboulis, Evangelos J.</creatorcontrib><creatorcontrib>Jemec, Gregor B.E.</creatorcontrib><creatorcontrib>Katoulis, Alexandros C.</creatorcontrib><creatorcontrib>Koenig, Anke</creatorcontrib><creatorcontrib>Lazaridou, Elizabeth</creatorcontrib><creatorcontrib>Marzano, Angelo V.</creatorcontrib><creatorcontrib>Matusiak, Łucas</creatorcontrib><creatorcontrib>Molina-Leyva, Alejandro</creatorcontrib><creatorcontrib>Moltrasio, Chiara</creatorcontrib><creatorcontrib>Pinter, Andreas</creatorcontrib><creatorcontrib>Potenza, Concetta</creatorcontrib><creatorcontrib>Romaní, Jorge</creatorcontrib><creatorcontrib>Saunte, Ditte M.</creatorcontrib><creatorcontrib>Skroza, Nevena</creatorcontrib><creatorcontrib>Stergianou, Dimitra</creatorcontrib><creatorcontrib>Szepietowski, Jacek</creatorcontrib><creatorcontrib>Trigoni, Anastasia</creatorcontrib><creatorcontrib>Vilarrasa, Eva</creatorcontrib><creatorcontrib>van der Zee, Hessel H.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American Academy of Dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Straalen, Kelsey R.</au><au>Tzellos, Thrasyvoulos</au><au>Guillem, Phillipe</au><au>Benhadou, Farida</au><au>Cuenca-Barrales, Carlos</au><au>Daxhelet, Mathilde</au><au>Daoud, Mathieu</au><au>Efthymiou, Ourania</au><au>Giamarellos-Bourboulis, Evangelos J.</au><au>Jemec, Gregor B.E.</au><au>Katoulis, Alexandros C.</au><au>Koenig, Anke</au><au>Lazaridou, Elizabeth</au><au>Marzano, Angelo V.</au><au>Matusiak, Łucas</au><au>Molina-Leyva, Alejandro</au><au>Moltrasio, Chiara</au><au>Pinter, Andreas</au><au>Potenza, Concetta</au><au>Romaní, Jorge</au><au>Saunte, Ditte M.</au><au>Skroza, Nevena</au><au>Stergianou, Dimitra</au><au>Szepietowski, Jacek</au><au>Trigoni, Anastasia</au><au>Vilarrasa, Eva</au><au>van der Zee, Hessel H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study</atitle><jtitle>Journal of the American Academy of Dermatology</jtitle><addtitle>J Am Acad Dermatol</addtitle><date>2021-08-01</date><risdate>2021</risdate><volume>85</volume><issue>2</issue><spage>369</spage><epage>378</epage><pages>369-378</pages><issn>0190-9622</issn><eissn>1097-6787</eissn><abstract>Tetracyclines and clindamycin plus rifampicin combination therapy are both considered first-line therapy in current hidradenitis suppurativa guidelines. However, evidence for their efficacy is drawn from small studies, often without validated outcomes.
To assess the 12-week efficacy of oral tetracyclines and a combination of clindamycin and rifampicin.
A prospective, international cohort study performed between October 2018 and August 2019.
In total, 63.6% of the included 283 patients received oral tetracyclines, and 36.4% were treated with clindamycin and rifampicin. Both groups showed a significant decrease in International Hidradenitis Suppurativa Severity Score System from baseline (both P < .001). The Hidradenitis Suppurativa Clinical Response (HiSCR) was achieved in 40.1% and 48.2% of patients, respectively (P = .26). Patient characteristics or disease severity were not associated with the attainment of HiSCR or the minimal clinically important differences for the Dermatology Life Quality Index and pain.
Cohort study. Respectively, 23.9% and 19.4% of patients had to be excluded from the HiSCR analysis for the tetracycline and combination therapy group because of a low abscess and nodule count at baseline.
This study shows significant efficacy of both tetracycline treatment and clindamycin and rifampicin combination therapy after 12 weeks in patients with hidradenitis suppurativa. No significant differences in efficacy were observed between the 2 treatments, regardless of disease severity.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>33484766</pmid><doi>10.1016/j.jaad.2020.12.089</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0190-9622 |
| ispartof | Journal of the American Academy of Dermatology, 2021-08, Vol.85 (2), p.369-378 |
| issn | 0190-9622 1097-6787 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2480265125 |
| source | Elsevier ScienceDirect Journals |
| subjects | acne inversa antibiotics clindamycin doxycycline efficacy guideline minocycline outcome rifampicin tetracycline therapy treatment |
| title | The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T19%3A28%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20efficacy%20and%20tolerability%20of%20tetracyclines%20and%20clindamycin%20plus%20rifampicin%20for%20the%20treatment%20of%20hidradenitis%20suppurativa:%20Results%20of%20a%20prospective%20European%20cohort%20study&rft.jtitle=Journal%20of%20the%20American%20Academy%20of%20Dermatology&rft.au=van%20Straalen,%20Kelsey%20R.&rft.date=2021-08-01&rft.volume=85&rft.issue=2&rft.spage=369&rft.epage=378&rft.pages=369-378&rft.issn=0190-9622&rft.eissn=1097-6787&rft_id=info:doi/10.1016/j.jaad.2020.12.089&rft_dat=%3Cproquest_cross%3E2480265125%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2480265125&rft_id=info:pmid/33484766&rft_els_id=S0190962221001766&rfr_iscdi=true |